𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer

✍ Scribed by Joan Morote; Inés de Torres; Carme Caceres; Carlos Vallejo; Simó Schwartz Jr.; Jaume Reventos

Publisher
John Wiley and Sons
Year
1999
Tongue
French
Weight
327 KB
Volume
84
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

It is well established that the activation of proto-oncogenes could trigger uncontrolled cell growth and cancer development. Although this correlation has already been evidenced in several human tumors, no conclusive studies have related oncogene activation with the development of prostatic neoplasia. Nevertheless, some reports suggest that c-erbB-2, which is a prognostic marker in breast cancer, could be implicated in the development of prostatic adenocarcinoma. We have studied the expression of the c-erbB-2 oncoprotein in primary prostatic tissue in a series of 70 patients with metastasic disease, by means of immunohistochemistry. The NCL-B 11 anti-c-erbB-2 monoclonal antibody was used, and the immunoreactivity was quantified by image analysis. The overall rate of prostatic-tissue sections presenting positive c-erbB-2 immunostaining was 64.3%. No significant relation was observed between histological grade and c-erbB-2 overexpression or severity of the disease, based on the extent of metastases. The average specific survival in patients with c-erbB-2 over-expression was 33 months, while it was 54 in patients with c-erbB-2 negativity; p F 0.034. These results, as well as the logistic-regression analysis, suggest that expression of c-erbB-2 oncoprotein would be considered as an independent prognostic factor of metastatic prostate cancer. Moreover, it could discriminate between the prognosis of patients with Gleason score 2 to 7 and those with score 8 to 10. Our results suggest that the expression of c-erbB-2 oncoprotein in primary prostatic tissue could have a prognostic value in patients with metastatic prostate cancer.

📜 SIMILAR VOLUMES

Prognostic significance of c-erbB-2 onco
Prognostic significance of c-erbB-2 oncoprotein expression in intestinal-type adenocarcinoma of the sinonasal tract
✍ Oreste Gallo; Alessandro Franchi; Isabelle Fini-Storchi; Gennaro Cilento; Vieri 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

## Background: The c-erbb-2 gene codes for a putative transmembrane protein, similar in structure to the epidermal growth factor receptor. amplification and/or overexpression of the gene has been recently described with a prognostic significance in a variety of human adenocarcinomas. ## Methods:

Prognostic value of p53, bcl-2, and c-er
Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas
✍ de Krijger, Ronald R.; van der Harst, Erwin; van der Ham, Frieda; Stijnen, Theo; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 260 KB 👁 2 views

Many studies have tried to discriminate malignant from benign phaeochromocytomas, but until now no widely accepted histological, immunohistochemical, or molecular methods have been available. In this study of 29 malignant and 85 benign phaeochromocytomas from 102 patients, immunohistochemistry was p

c-erbB2 oncoprotein expression, gene amp
c-erbB2 oncoprotein expression, gene amplification, and chromosome 17 aneusomy in apocrine adenosis of the breast
✍ Selim, Abdel-Ghani A.; El-Ayat, Ghada; Wells, Clive A. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 1 views

Ampli®cation of the c-erbB2 oncogene and numerical aberrations of chromosome 17 occur in human breast carcinomas. Apocrine adenosis (AA) of the breast has been shown occasionally to have c-erbB2 overexpression and a possible premalignant potential, but little is known about cellular level genetic al

Proliferating cell nuclear antigen and c
Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands
✍ Kyung-Ja Cho; Seung-Sook Lee; Yong-Sik Lee 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 1 views

Background. Adenoid cystic carcinoma (ACC) of the salivary gland shows a variable clinical course. It would be helpful to discover reliable biologic markers in the management of patients with ACC. Methods. We examined proliferating cell nuclear antigen (PCNA) and c-erbB-2 oncoprotein expression on

No significant predictive value of c- er
No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
✍ Sylvie Rozan; Anne Vincent-Salomon; Brigitte Zafrani; Pierre Validire; Patricia 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 325 KB 👁 1 views

To document whether c-erbB-2 over-expression or p53 accumulation in tumour cells was predictive of response to chemo-or radiotherapy, we analyzed a population of patients with breast cancer assigned to neo-adjuvant therapy (median follow-up: 54 months). T2/T3-N0N1b-M0 tumours (329 cases) were treate